TWST - Twist Bioscience Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
25.61
+1.27 (+5.22%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close24.34
Open24.06
Bid21.00 x 800
Ask0.00 x 800
Day's Range23.95 - 26.45
52 Week Range12.38 - 34.46
Volume1,127,011
Avg. Volume183,190
Market Cap814.139M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-6.50
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.50
Trade prices are not sourced from all markets
  • Business Wire4 days ago

    Twist Bioscience to Present at the UBS Global Healthcare Conference

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder, will present at the UBS Global Healthcare Conference on Monday, May 20th at 11:30 a.m. ET. Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.

  • Twist Bioscience (TWST) Catches Eye: Stock Jumps 8%
    Zacks6 days ago

    Twist Bioscience (TWST) Catches Eye: Stock Jumps 8%

    Twist Bioscience (TWST) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

  • Business Wire7 days ago

    Twist Bioscience Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the closing of its upsized underwritten public offering of 4,312,500 shares of its common stock at a public offering price of $21.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 562,500 shares of common stock in this offering. A registration statement relating to the securities sold in this offering was filed with the Securities and Exchange Commission and declared effective on May 8, 2019. This offering was made solely by means of a prospectus forming part of the effective registration statement.

  • Business Wire11 days ago

    Twist Bioscience Announces Pricing of $78.8 Million Public Offering of Common Stock

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pricing of its underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $21.00 per share, before underwriting discounts and commissions. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.

  • Business Wire14 days ago

    Twist Bioscience Announces Proposed Public Offering of Common Stock

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock.

  • Twist Bioscience Delivers Steep Loss in Fiscal Q2 2019
    Motley Fool18 days ago

    Twist Bioscience Delivers Steep Loss in Fiscal Q2 2019

    The DNA synthesis leader is pouring money into R&D and hoping it finds a sustainable business model. That's riskier than investors might realize.

  • Twist Bioscience Corporation (TWST) Q2 2019 Earnings Call Transcript
    Motley Fool19 days ago

    Twist Bioscience Corporation (TWST) Q2 2019 Earnings Call Transcript

    TWST earnings call for the period ending March 31, 2019.

  • Associated Press20 days ago

    Twist Bioscience: Fiscal 2Q Earnings Snapshot

    The San Francisco-based company said it had a loss of 93 cents per share. The maker of synthetic DNA for the biotechnology industry posted revenue of $13.6 million in the period, surpassing Street forecasts. ...

  • Business Wire20 days ago

    Twist Bioscience Reports Second Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress

    -- Reports Record Revenue of $13.6 Million for Second Quarter of Fiscal 2019 --

  • Business Wire25 days ago

    Twist Bioscience Announces Synthetic DNA Biosecurity Publication in Frontiers

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a new biosecurity publication titled ‘Next Steps for Access to Safe, Secure DNA Synthesis’, highlighting specific steps, in part derived from successes in the cybersecurity community, that ensure DNA synthesis screening (screening both the sequence and the customer) stays well ahead of emerging challenges and continues to enable responsible research advances. “Manufacturing synthetic DNA at increased scale and complexity holds tremendous promise to advance the progress in the grand challenges facing our world,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

  • Business Wirelast month

    Twist Bioscience to Report Fiscal 2019 Second Quarter Financial Results on Tuesday, April 30, 2019

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that it will issue its financial results for the fiscal 2019 second quarter ended March 31, 2019, following the close of market on Tuesday, April 30, 2019. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website prior to the conference call through the Investor Relations section under the “Company” tab at www.twistbioscience.com.

  • Business Wirelast month

    Twist Bioscience and iGEM Partner to Provide Synthetic DNA for iGEM Competition and Registry

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and the International Genetically Engineered Machine (iGEM) Foundation today announced a collaboration to change the way iGEM Competition teams contribute to the Registry of Standard Biological Parts, a free online database for synthetic biologists. A standard biological part is a functional unit of DNA that encodes for a specific biological function (such as a response to stimuli, or the synthesis of interesting proteins), and conforms to a construction standard. Parts from the Registry can be mixed and matched to build synthetic biology devices and systems.

  • Business Wirelast month

    Twist Bioscience Announces Antibody Optimization Agreement with Pandion Therapeutics

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a new collaboration with Pandion Therapeutics, to apply its antibody optimization platform to the targeting arm of a bispecific antibody. Pandion Therapeutics is a biotechnology platform company developing therapeutics to achieve localized immunomodulation to treat autoimmune and inflammatory disease.

  • Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session
    Zackslast month

    Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session

    Twist Bioscience (TWST) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Business Wirelast month

    Twist Bioscience Customized Libraries for Biologics Discovery Highlighted at PEGS Boston 2019

    - Proof-of-Concept Data Presented for GPCR Library and Antibody Optimization Solution –

  • Business Wirelast month

    Twist Bioscience Adopts Battelle’s ThreatSEQ™ DNA Screening Web Service for Advanced Biosecurity

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it is the first to implement Battelle’s ThreatSEQ™ web service DNA screening platform for the detection and characterization of sequences of concern in genomic data, supplementing its internal biosecurity efforts. “We have spent decades working with and characterizing biothreats to support global biodefense efforts, which has resulted in the curation of a high-quality Sequence of Concern database and the development of a robust algorithm for screening DNA at production scale rapidly,” said Matt Vaughan, President of Battelle’s Contract Research business.

  • Business Wire2 months ago

    Twist Bioscience and LakePharma Form Strategic Collaboration to Provide Antibody Discovery and Development Services

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and LakePharma, Inc., the leading US-based biologics CRDMO, today announced a strategic collaboration to offer antibody discovery and development solutions to pharmaceutical and biotechnology customers. Under the terms of the agreement, LakePharma will have the ability to offer Twist’s proprietary antibody discovery and optimization platforms to their existing and future biopharmaceutical customers as part of their service offerings. One such platform generated is for discovery of novel therapeutic antibodies against a major class of protein drug targets known as GPCRs, which traditionally have been difficult for biologics drug development.

  • Business Wire2 months ago

    Twist Bioscience Announces Presentations and User Group Meeting at PEGS Boston 2019

    -- Aaron Sato, Ph.D., Chief Scientific Officer of Twist Biopharma, to Deliver Keynote Address –

  • Business Wire2 months ago

    Twist Bioscience to Present at Cowen 39th Annual Healthcare Conference

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder, will present at the 39th Annual Cowen Healthcare Conference on Tuesday, March 12th at 11:20 a.m. Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.

  • Twist Bioscience Showcases Next-Generation Sequencing Solutions at the 2019 Advances in Genome Biology and Technology Meeting
    Business Wire3 months ago

    Twist Bioscience Showcases Next-Generation Sequencing Solutions at the 2019 Advances in Genome Biology and Technology Meeting

    -- New Features Enable Sample to Sequencer in a Single Day –

  • Associated Press3 months ago

    Twist Bioscience: Fiscal 1Q Earnings Snapshot

    The San Francisco-based company said it had a loss of $1.18 per share. The maker of synthetic DNA for the biotechnology industry posted revenue of $11.5 million in the period, surpassing Street forecasts. ...

  • Business Wire3 months ago

    Twist Bioscience Reports First Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress

    -- Reports Record Revenue of $11.5 Million for First Quarter of Fiscal 2019 --

  • Business Wire3 months ago

    Twist Bioscience Announces Appointment of Martin Kunz as Senior Vice President, Operations

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA manufactured on its silicon platform, today announced the appointment of Martin Kunz as senior vice president of operations.

  • Business Wire4 months ago

    Twist Bioscience Chief Technology Officer Presented at Praesens Foundation Future Health Threats Initiative 2019

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that Bill Peck, Ph.D., chief technology officer, participated in the Future Health Threats Initiative 2019, a conference designed to encourage public-private cooperation to strengthen health security in Africa. The Praesens Foundation is operating at the intersection of global health technology innovation and social impact.

  • What's next for this slow-moving Peninsula biotech IPO?
    American City Business Journals4 months ago

    What's next for this slow-moving Peninsula biotech IPO?

    The company filed in late September for a $75 million initial public offering but has yet to release any more information, even as a key partnership hits major milestones.